Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma
Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma
复制标题
DOI：
10.1002/cncr.32411
复制
发表时间：
2019-09-10
期刊：
影响因子：
6.2
通讯作者：
Davis, Benjamin
中科院分区：
文献类型：
--
作者：
Abramson, Jeremy S.;Irwin, Kelly E.;Davis, Benjamin
HIV阳性患者已被排除在评估嵌合抗原受体（CAR）T细胞疗法的临床试验之外。在本文中，作者报告了2例HIV/AIDS相关的化疗难治性侵袭性B细胞淋巴瘤患者，他们成功地用抗CD 19 CAR T细胞产品axicabtagene ciloleucel治疗。
HIV-positive patients have been excluded from clinical trials evaluating chimeric antigen receptor (CAR) T-cell therapies. Herein, the authors report on 2 patients with HIV/AIDS-associated, chemotherapy-refractory, aggressive B-cell lymphomas who were treated successfully with the anti-CD19 CAR T-cell product axicabtagene ciloleucel.